Holen Sie sich die Stockscreener-App
0.8223
2.40%
-0.0202
Handel nachbörslich:
.84
0.0177
+2.15%
Schlusskurs vom Vortag:
$0.8425
Offen:
$0.8656
24-Stunden-Volumen:
30,374
Relative Volume:
0.02
Marktkapitalisierung:
$4.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.72M
KGV:
-0.1499
EPS:
-5.4871
Netto-Cashflow:
$-5.47M
1W Leistung:
+9.15%
1M Leistung:
-26.58%
6M Leistung:
-54.94%
1J Leistung:
-72.77%
1-Tages-Spanne:
$0.8217
$0.8656
1-Wochen-Bereich:
$0.7311
$0.8798
52-Wochen-Spanne:
$0.7311
$3.50
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.8223 | 4.62M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
EBIT per share of Galmed Pharmaceuticals Ltd. – BER:GPH - TradingView — Track All Markets
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025Market Sentiment Surveys & Free Rapid Wealth Multiplication - bollywoodhelpline.com
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Evening Star Patterns & High Profit Market Ideas - bollywoodhelpline.com
Downgrade Watch: Why Galmed Pharmaceuticals Ltd stock is seen as undervalued2025 Short Interest & Weekly Breakout Stock Alerts - moha.gov.vn
Financial Survey: Galmed Pharmaceuticals (NASDAQ:GLMD) vs. Qualigen Therapeutics (NASDAQ:QLGN) - Defense World
Will Galmed Pharmaceuticals Ltd. stock benefit from upcoming earnings reportsJuly 2025 Review & Low Drawdown Investment Strategies - Улправда
Aug Selloffs: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Key Lessons & Long-Term Growth Portfolio Plans - Улправда
How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stock2025 Price Action Summary & Daily Stock Trend Watchlist - Улправда
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
How big funds are accumulating Galmed Pharmaceuticals Ltd. (GPH) stockMarket Capitalization Trends & Outperform the Market with Aggressive Picks - Bollywood Helpline
Is Galmed Pharmaceuticals Ltd. (GPH) stock a safe buy pre earningsMarket Trend Review & Weekly Top Gainers Trade List - DonanımHaber
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Canada
Galmed to present data on Aramchol’s potential in liver cancer - Investing.com
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed Pharmaceuticals’ Aramchol abstract accepted for HEP-DART 2025 presentation - MSN
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - PR Newswire
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed stock rises after patent grant for MASH combo therapy - Investing.com
Galmed receives patent for combination therapy in South Korea - Investing.com
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - PR Newswire
Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser
Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Galmed reports $19.2 million cash position, advances Aramchol programs By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):